Cannabis and Dermatitis

Plain-language summary

Dermatitis is an umbrella term for inflamed, itchy skin. The most common forms are atopic dermatitis (eczema), contact dermatitis (irritant or allergic), and seborrheic dermatitis. Cannabis has come up as a possible treatment because the skin has its own endocannabinoid system — cannabinoid receptors (CB1, CB2) and related enzymes are expressed on keratinocytes, sebocytes, immune cells, and nerve endings in the skin ^[1][2]. In theory, activating this system could calm inflammation and itch.

In practice, the human evidence is thin. There are small open-label studies on topical CBD and on palmitoylethanolamide (PEA, an endocannabinoid-like molecule), some lab and animal work, and a lot of marketing. There are no large, blinded, randomized trials proving that any cannabis-derived product treats eczema. This article walks through what is actually supported, what is plausible but unproven, and what is folklore.

This article is not medical advice. Talk to a dermatologist before replacing any prescribed treatment with a cannabis product.

What probably works (relatively speaking)

Honestly, nothing in cannabis has reached the bar of probably works for dermatitis in the way that topical corticosteroids or calcineurin inhibitors have. The closest claims:

• Bland emollient effect of hemp seed oil. Cold-pressed hemp seed oil is essentially a fatty acid-rich vegetable oil (high in linoleic and alpha-linolenic acid). A small randomized crossover trial in atopic dermatitis patients found dietary hemp seed oil improved dryness and itch versus olive oil ^[3]. The effect is most plausibly from polyunsaturated fatty acids, not cannabinoids — hemp seed oil contains essentially no THC or CBD. Weak / limited
• PEA-containing creams for itch and barrier repair. Palmitoylethanolamide is an endogenous fatty acid amide that interacts with the endocannabinoid system indirectly. A large open-label observational study ("ATOPA") in over 2,000 atopic dermatitis patients reported reduced itch, redness, and topical steroid use with a PEA-containing cream ^[4]. Open-label, no placebo, sponsor-affiliated — so treat the numbers with caution. Weak / limited

That is the upper end of the current evidence.

What might work

• Topical CBD for inflammation and itch. Lab studies show CBD reduces inflammatory cytokines in keratinocyte cultures and dampens mast cell activation ^[2][5]. A small open-label study of a CBD-containing ointment in 20 patients with psoriasis or atopic dermatitis reported improvements in skin parameters and sleep, but had no control group ^[6]. Weak / limited
• Cannabinoids for chronic pruritus. A small uncontrolled study of a cream containing endocannabinoids (N-palmitoylethanolamine) in patients with uremic pruritus reported reduced itch ^[7]. Mechanistically, CB1 activation on peripheral nerve endings can reduce itch signaling ^[1]. Weak / limited
• CBG and other minor cannabinoids. Almost entirely preclinical. Interesting in cell models, no controlled human dermatitis data. No data
• Oral cannabinoids for itch in cholestatic or systemic disease. A few case reports describe dronabinol reducing intractable pruritus ^[8]. Not a dermatitis study, but adjacent. Weak / limited

What doesn't work, or has weak evidence

• "CBD cures eczema." No. There are no controlled trials supporting a cure or even reliable remission. No data
• Smoking or vaping cannabis to treat eczema. No clinical evidence. Inhaled cannabis raises systemic THC, which has unpredictable immune effects, and combustion products are pro-inflammatory. No data
• "Indica strains calm skin, sativa strains irritate it." Folklore. The indica/sativa split does not reliably predict chemistry, let alone skin effects. See Indica vs Sativa. No data
• High-THC topicals for contact dermatitis. No controlled data. THC is lipophilic and absorbs poorly through intact skin from typical topicals ^[9], so claims of dramatic local effects should be viewed skeptically. Weak / limited
• Hemp seed oil as a "cannabinoid" treatment. It works (modestly) as an emollient, but it is not delivering meaningful CBD or THC. Don't pay cannabinoid prices for it. Disputed

What we don't know

• Whether topical CBD outperforms a well-formulated vehicle (moisturizer) alone in a blinded trial. No adequate RCT exists.
• The right dose. CBD topical products range from <0.1% to >5% with no evidence-based target.
• Whether cannabinoids help, hurt, or have no effect on the skin microbiome in atopic dermatitis.
• Long-term safety of daily topical cannabinoid use on inflamed, barrier-disrupted skin (which absorbs more than healthy skin).
• Whether oral or inhaled cannabis modifies atopic disease course. The limited epidemiological data are inconsistent.
• Drug interactions when topical CBD is used over large body surface areas in patients on systemic immunomodulators.

Comparison with standard treatments

Standard dermatology for atopic dermatitis, per AAD and EuroGuiDerm guidelines ^[10][11], is a ladder:

1. Emollients and trigger avoidance — first line for everyone.
2. Topical corticosteroids — decades of RCT evidence, strong effect, well-characterized risks (skin thinning with prolonged high-potency use).
3. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) — steroid-sparing, good evidence.
4. Topical JAK inhibitors (e.g., ruxolitinib) and PDE4 inhibitors (crisaborole) — newer, RCT-supported.
5. Phototherapy and systemic agents — dupilumab, tralokinumab, oral JAK inhibitors for moderate-severe disease.

No cannabis-derived product has cleared the bar required to enter this ladder. A CBD or PEA cream is, at best, a fancy emollient — i.e., it might help at the bottom rung, where any decent moisturizer would also help. It is not a substitute for steroids, calcineurin inhibitors, or biologics in moderate-to-severe disease.

For contact dermatitis, the standard is identifying and removing the trigger plus short-course topical steroids. There is no good evidence that cannabis products improve on this, and — importantly — cannabis itself can cause contact dermatitis.

Risks and adverse effects

• Cannabis-induced allergic contact dermatitis. Documented in case reports and small series, particularly in growers, trimmers, and frequent topical users; sensitization to Cannabis sativa proteins and to terpenes like linalool and limonene is real ^[12]. Strong evidence for existence; uncommon overall.
• Irritant reactions from carrier ingredients. Many CBD topicals contain essential oils, fragrances, and preservatives that themselves trigger dermatitis. Read the full ingredient list.
• Product quality. Independent testing has repeatedly found CBD products mislabeled for potency, and some contain detectable THC, pesticides, or heavy metals ^[13]. For broken skin, contamination matters more than for intact skin.
• Systemic absorption. Through barrier-disrupted eczematous skin, more drug enters the body than through healthy skin. Daily whole-body application of a high-strength CBD product is not a zero-exposure intervention.
• Drug interactions. Oral CBD inhibits CYP3A4/2C19 and interacts with many drugs ^[14]. Topical exposure is usually low but not necessarily zero with large surface areas.
• Delay of effective care. The biggest practical harm: people with worsening eczema using cannabis products instead of seeing a dermatologist, leading to infection, sleep loss, and scarring.

---

This article is not medical advice. It is a summary of published evidence as of writing. If you have dermatitis — especially if it is widespread, infected, painful, or affecting sleep — see a clinician. Tell them about any cannabis or CBD products you use, including topicals.

Sources

How this page was made